H uman genetics has the potential to identify novel mechanisms for disease, which in turn present opportunities for clinical translation. Over the past 10 years, genome-wide association studies (GWAS) have identified over 400 genomic regions robustly associated with type 2 diabetes (T2D) risk, and have highlighted a central role for pancreatic β -cell dysfunction in T2D pathogenesis [1] [2] [3] [4] . However, translating GWAS signals into molecular mechanisms for disease has been slow, primarily because of uncertainty over the transcripts through which non-coding association signals operate 5 . Recently, studies focused on identifying coding variant association signals have identified non-synonymous alleles in peptidylglycine α -amidating monooxygenase (PAM) independently that are associated with a risk of T2D (rs78408340, NM_000919.3, c.1616C > G, odds ratio (OR) = 1.47, minor allele frequency (MAF) = 7.3 × 10 −3 in Europeans; rs35658696, NM_000919.3, c.1688A > G, OR = 1.23, MAF = 0.045), providing a direct link to the effector transcript 3, 6, 7 . Although the low-frequency variant at rs35658696 was in linkage disequilibrium with a coding variant in a nearby gene (PPIP5K2; rs36046591), recent fine-mapping efforts have confirmed rs35658696 as the causal variant 4 . Both T2D risk alleles are also associated with a reduced insulinogenic index (rs78408340, β = − 8.42; rs35658696, β = − 1.96)-a measure of glucose-stimulated insulin secretion-suggesting that their effects are mediated via altered β -cell function 6, 8, 9 . PAM encodes PAM, an enzyme in neuroendocrine cells that modifies peptides with a C-terminal glycine residue to create peptide amides [10] [11] [12] . Amidation can dramatically increase the biological potency of a peptide relative to its unmodified glycine-extended conjugate 13 . PAM is localized to the Golgi complex, where it is packaged with other endocrine proteins into nascent granules 10, 14 .
The functional enzyme exists in both integral membrane and luminal forms; the latter is co-secreted with the endocrine peptide(s) 10, 11, 15 . Despite reports of PAM expression in pancreatic islets, a functional role in β -cells has not yet been described 16 . Insulin itself is not a PAM substrate, so the association of PAM variants with an insulinogenic index must be mediated via other peptide(s) or mechanisms. We hypothesized that T2D-associated PAM missense alleles reduce PAM function, affecting the amidation of peptides that is critical for insulin secretion. We demonstrate that both diabetes risk alleles negatively impact on PAM expression and/or activity, and elucidate an endogenous role for PAM in insulin granule packaging and release from β -cells. We also show that PAM amidates the granule packaging factor chromogranin A (CgA), and identify this neuroendocrine peptide as a likely downstream effector for PAM in β -cells. Our results are consistent with the direction and magnitude of effects for T2D-associated risk alleles in PAM, and establish molecular mechanisms for their impact on disease susceptibility.
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NATure GeNeTiCs membrane) PAM protein for in vitro amidation assays using human embryonic kidney 293 (HEK293) cells as a suitable human expression system. In line with previous observations, PAM was constitutively released into the supernatant (Fig. 1a ) 17 . Wild-type PAM and p.Asp563Gly PAM were both robustly produced. Additionally, a catalytically inactive mutant protein, p.Tyr651Phe PAM, was also produced, which was used as a control 18 . Interestingly, we could not detect p.Ser539Trp PAM expression 
NATure GeNeTiCs (Fig. 1a) . This was observed across three independently derived cell lines, and was not due to cellular retention of p.Ser539Trp PAM (data not shown).
We subsequently developed a cell-free kinetic assay capable of measuring PAM amidating activity via spectrophotometric detection of converted glyoxylate, a by-product of the amidation reaction 19, 20 . Matching each reaction for PAM input, we observed reduced amidating activity for p.Asp563Gly (D563G) PAM (P = 1.0 × 10 −5
) and p.Tyr651Phe (Y651F) PAM (P = 4.1 × 10 −6 ) (Fig. 1b) . In agreement with its lack of expression, supernatant from p.Ser539Trp (S539W) PAM-transfected cells was inactive in this assay ( Supplementary Fig. 1a ). Further analysis showed no significant difference in substrate affinity between wild-type PAM and p.Asp563Gly PAM (substrate concentration which gives half maximal velocity of the enzymatic reaction [K m ] 0.95 mmol.l −1 versus 1.02 mmol.l -1 , P = 0.44), suggesting that the p.Asp563Gly substitution affects the number of substrate molecules converted over time (K cat )( Supplementary Fig. 1b ). These results demonstrate that the T2D-associated missense alleles in PAM decrease PAM function via a combination of defective expression and/or reduced catalysis.
PAM localizes to the β-cell secretory pathway. Having established the direction of effect for T2D risk alleles in PAM, we next explored a role for PAM in physiologically relevant tissues. Transcript expression profiling detected PAM in multiple tissue types, with the highest expression in human islets followed by the heart and salivary glands ( Supplementary Fig. 2a ). In mouse tissues, Pam expression was highest in the pituitary gland (not included in the human panel) followed by the heart and islets ( Supplementary Fig. 2a ). These results are consistent with the published association between PAM risk alleles and reduced measures of insulin secretion, and suggest a direct role for PAM in β -cell function. We confirmed broadly similar expression patterns in the publicly available Genotype Tissue Expression (GTEx) database, although data for pancreatic islets are not available from this project 21 . Published RNA sequencing data also showed PAM to be equally expressed in enriched fractions of β -cells and non-β -cells ( Supplementary Fig. 2a ) 22, 23 . We verified this expression pattern at the protein level by performing immunofluorescence and electron microscopy of primary human islets, which showed co-localization of endogenous PAM in both insulin and glucagon vesicles (Fig. 2a,b) . We also confirmed PAM localization to the insulin secretory pathway of the glucose-responsive human β -cell model EndoC-β H1 (Fig. 2c ) 24, 25 . These observations are in agreement with early studies that established PAM expression and activity in endocrine cells of human and murine islets [26] [27] [28] [29] .
We then performed detailed analysis of the subcellular localization of wild-type and variant PAM for both integral and luminal forms of the protein in EndoC-β H1 cells. Integral membrane wildtype PAM localized to the trans-Golgi network (TGN), where secretory granules originate, whereas luminal wild-type PAM displayed a punctate staining pattern and co-localized with endogenous insulin (Fig. 1c,d ). Similar results were observed for p.Asp563Gly PAM and p.Tyr651Phe PAM (Supplementary Fig. 2b ). As in HEK293 cells, luminal p.Ser539Trp PAM expression was undetectable (Fig. 1d) ; however, integral membrane p.Ser539Trp PAM displayed an aberrant staining pattern that localized to the endoplasmic reticulum as well as the TGN (Fig. 1c and Supplementary Fig. 2b ). These results confirm that PAM localizes to components of the β -cell secretory pathway, in agreement with studies in other neuroendocrine cell types 10, 14, [30] [31] [32] . The p.Ser539Trp substitution may interfere with PAM protein folding, so that its translocation from the endoplasmic reticulum to the TGN is prevented or delayed.
Impact of risk variants on PAM expression.
Given that luminal isoforms of PAM are known to be co-secreted with neuroendocrine peptides, we next wondered whether the impact of the p.Ser539Trp substitution would be reflected in lower circulating PAM levels in the bloodstream. Analyzing publicly available data from a human plasma proteome study by Sun et al. 33 , we confirmed a significant decrease in the concentration of PAM for rs78408340 risk allele carriers (β = − 1.53 per risk allele, 95% confidence interval (CI) (− 1.84, − 1.22), P = 5.6 × 10 −22 , in standard deviation units of PAM levels), consistent with our in vitro observations in both HEK293 and EndoC-β H1 cells.
Interestingly, we also found that the T2D risk allele at rs35658696 was associated with reduced PAM protein levels in plasma (β = − 0.97 per risk allele, 95% CI (− 1.09, − 0.85), P = 1.5 × 10
−67
). To determine whether this effect could be mediated via regulatory effects on PAM gene expression, we analyzed RNA sequencing and genotype data from the largest available cohort of islets, which consisted of a combined collection of islets from Edmonton, Canada and Oxford, UK 34 . Out of a total of 118 donors, 11 individuals were identified as heterozygous for rs35658696. After correcting for potential mapping biases using WASP 35 , allele-specific expression revealed a significant imbalance (P = 1.76 × 10
−4
). The overall difference was relatively modest (53.2% versus 46.8%), but the imbalance was biased toward higher expression of the reference allele ( Supplementary Fig. 3 ). This is directionally consistent with the negative functional impact of the minor allele on PAM amidation, highlighting a potential exacerbation of the reduction in PAM activity in risk allele carriers.
Finally, to identify a possible mechanism underlying this apparent difference in regulatory activity at rs35658696, we searched for genomic annotations overlapping the risk variant in reported 
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NATure GeNeTiCs chromatin states for human pancreatic islets 36 . This was extended to consider all variants in linkage disequilibrium (r 2 > 0.8) with the lead SNP. The predicted causal variant (rs35658696) overlapped annotations indicative of gene enhancer activity; two variants in strong linkage disequilibrium (r 2 > 0.97) with the causal variant overlapped weak enhancer annotations (Supplementary Table 1 ). These observations provide a framework for understanding the effect of the T2D risk allele on PAM transcript levels, although a more detailed mechanistic interrogation is outside the scope of this study.
Taken together, these results confirm the association of the rs78408340 (p.Ser539Trp) risk allele with reduced PAM protein levels and point to a regulatory component of the causal mechanism underlying the rs35658696 (p.Asp563Gly) risk allele. The latter effect may be relatively smaller than the functional impact on catalytic activity. Nevertheless, the effects are directionally aligned, thus compounding the negative effect of the risk allele through a dual mechanism of deficiencies in both catalytic function and expression.
PAM regulates glucose-responsive insulin secretion. In light of the negative impact of both T2D risk alleles on overall PAM function, we next determined the effects of reduced PAM levels on β -cell activity. Small interfering RNA (siRNA)-mediated knockdown of PAM in EndoC-β H1 cells caused a 79% reduction in PAM transcript levels ( Supplementary Fig. 4a ). This was associated with significantly decreased insulin secretion in high glucose (− 14.4%; P = 5.6 × 10 −5 ), but not in basal glucose (− 6.9%; P = 0.39) (Fig. 3a) . Furthermore, PAM knockdown cells displayed a significantly blunted response to glucose (ratio of high to basal secretion, − 7.7%; P = 0.03), which is indicative of a greater impact on secretion under stimulated conditions. Cellular insulin content was also reduced in PAM knockdown cells (− 17.6%; P = 4.9 × 10 −5 ) despite normal viability and insulin (INS) gene expression ( Fig. 3b-d) . As a result, secretion measures could be normalized by adjusting for insulin content (that is, expressing secretion as a percentage of content), with no significant defects for small interfering PAM (siPAM) cells ( Supplementary Fig. 5a-d) . We also noted that content-adjusted rates of insulin secretion were not further impacted by stimulation with either depolarizing KCl or the 3′ , 5′ -cyclic adenosine monophosphate (cAMP)-elevating agent forskolin (Supplementary Fig. 6a ). This indicates that the reductions in insulin secretion following PAM knockdown are not caused by a defect in calcium entry or total granule exocytosis.
We next performed quantitative electron microscopy using immunogold labeling of PAM and insulin. The results of this analysis confirmed successful knockdown of PAM at the protein level, with a 47% reduction in the number of particles per vesicle (ppv) . P values * < 0.05, ** < 0.01 and *** < 0.001 for two-tailed Student's t-tests where a single independent variable was being tested (b-d), or for two-way analysis of covariance (ANCOVA) followed by Tukey's HSD post-hoc test where two experimental variables were being tested (a,e-g). All box plots display the interquartile range (IQR) with medians, whiskers indicating 1.5 × the IQR, and outliers (for n > 10) or all data points (for n < 10).
NATure GeNeTiCs (Fig. 4a,c) . siPAM-treated cells showed a 23% decrease in immunogold-labeled insulin per vesicle compared with control cells (6.26 ± 0.28 versus 8.1 ± 0.41 ppv; P = 1.77 × 10
) (Fig. 4a,b) , thus corroborating the pooled content measures described earlier. (Fig. 4d,e) . No qualitative differences in insulin crystallization were observed (Fig. 4f) .
To probe further the effect of PAM silencing on insulin secretion, we performed high-resolution, single-cell capacitance measurements. Following stimulation of individual cells with a train of ten depolarizations, an increase in plasma membrane surface area due to vesicle exocytosis could be detected at each step. The cumulative increase in exocytosis was comparable between PAM knockdown and control cells (43.9 ± 8.6 fF pF −1 versus 38.0 ± 8.1 fF pF (Fig. 3e) , and there was no difference in calcium entry (peak current 4.5 ± 0.7 pA pF −1 versus 3.6 ± 0.6 pA pF −1 for PAM knockdown versus control cells; P = 0.27) (Fig. 3g) . Moreover, the exocytotic response increased similarly with the calcium current amplitude in both control and PAM knockdown cells ( Supplementary Fig. 6b ), corroborating the normal calcium sensitivity inferred from secretion assays.
In contrast, the kinetics of vesicle release were significantly different; in controls cells, nearly 60% of the exocytotic response was elicited by the first pulse, compared with < 40% in PAM knockdown cells (P = 0.013) (Fig. 3f) . The increase in cell capacitance during the first two depolarizations provides an estimate for the size of the readily releasable pool (RRP) of secretory granules, whereas subsequent pulses represent mobilization of granules from the more intracellular reserve pool 37 . Thus, our results indicate that PAM is an endogenous regulator of the exocytotic response in pancreatic β -cells, with a specific effect on the availability of the RRP.
Effects of the rs35658696 risk variant on primary islet function.
Having established a role for PAM in a human β -cell model, we sought to corroborate our results by examining the effects of the low-frequency PAM variant (rs35658696) in primary islets. First, we analyzed insulin secretion and content measures for intact human islets isolated from cadaveric donors. In the Edmonton collection of functionally characterized islets, we identified 16 individuals heterozygous for the T2D risk allele ("carriers") and . Results shown are the average of n = 235 (scrambled) or n = 290 (PAM) vesicles, except for e, where n = 10 cells per treatment. f, Electron micrographs from EndoC-β H1 cells either non-transfected or siRNA-transfected, as indicated. Immature and mature insulin vesicles are highlighted by short and long arrows respectively. m, mitochondrion. P values * < 0.05, ** < 0.01, *** < 0.001 for two-tailed Student's t-tests. All box plots display the interquartile range (IQR) with medians, whiskers indicating 1.5 × the IQR, and outliers.
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16 age-, sex-, and body mass index (BMI)-matched donors homozygous for the reference allele ("controls"). All individuals were analyzed for insulin content, as well as secretion under basal (1 mM) and high (16.7 mM) glucose in sequential incubations. In a subset of nine individuals, insulin secretion was also assessed for an intermediate glucose level (10 mM).
We detected no significant change in insulin content (− 16.3%; P = 0.37), but we detected a highly significant reduction in overall insulin secretion for risk carriers compared with controls (P = 7.81 × 10 −4 by analysis of covariance (ANCOVA)) (Fig. 5 ). The effect on secretion showed a positive interaction with glucose levels (P = 0.041), highlighting a greater difference between risk carriers and controls under stimulated conditions. Thus, testing for pairwise significant differences, we identified no effect of carrier status in basal glucose (− 23.8%; P = 1.00), but a trend toward a reduction in intermediate glucose (− 58%; P = 0.073) and significantly decreased secretion in high glucose (− 49%; P = 0.016). Importantly, these defects in raw insulin secretion could be fully rescued by normalizing to insulin content (P = 0.88 by ANCOVA), with no significant pairwise differences (P = 1.00 for basal; P = 1.00 for intermediate; and P = 0.99 for high glucose) ( Supplementary  Fig. 7 ). Overall, our results establish a defect in intact islets from risk allele carriers highly concordant with that observed following PAM knockdown in the EndoC-β H1 model.
Next, we analyzed exocytosis in single β -cells from dispersed human islets, with capacitance measurements following a train of ten depolarizations in either 1 or 10 mM glucose. Seven individuals heterozygous for the T2D risk allele were compared to seven matched controls (Fig. 6a) . As with the insulin secretion measures from intact islets, we observed a statistically significant interaction between glucose level and genotype status (P = 2.83 × 10
by ANCOVA), with a greater negative effect of the risk allele under stimulated conditions (P = 1.22 × 10 −3 ) than in basal glucose (P = 0.48). To specifically test for differences in the RRP, we calculated the total increase in capacitance during the first two depolarizations (Fig. 6b) . Although no differences were detected in low glucose, a significant decrease in capacitance was seen in risk allele carriers at 10 mM glucose (− 26.5%; P = 0.04), which is indicative of reduced exocytosis from the RRP. Our results are therefore consistent with an effect of the rs35658696 genotype on the kinetics of granule release that manifests predominantly under stimulated conditions. Chromogranin A is a substrate and plausible downstream effector of PAM in β-cells. To elucidate the PAM-regulated pathway in β -cells, we finally sought to identify possible target proteins that could act as downstream effectors of PAM activity. While any C-terminal glycine-extended peptide could be a substrate for PAM, we reasoned that a key downstream mediator of the observed effects in β -cells would need to be co-expressed with PAM along the secretory pathway. Therefore, we searched a published catalog of the islet secretome for potential targets of PAM amidation 38 . This highlighted two proteins, chromogranin A (CgA, encoded by CHGA) and islet amyloid polypeptide (IAPP, encoded by IAPP), both of which are highly expressed in β -cells and have plausible links with PAM function. CgA is a granular packaging protein that self-aggregates to condense large numbers of neuroendocrine peptides into nascent secretory granules [39] [40] [41] . It can also be cleaved to produce smaller peptides with additional biological roles 42 . The role of IAPP in β -cells is less well understood, although it is known to be stored in secretory granules and co-released with insulin 43 . CHGA silencing (Supplementary Fig. 4b ) resulted in a phenotype similar to that observed for PAM, with significant reductions in both insulin content and secretion (Fig. 7a-c and Supplementary  Fig. 5e-h ). Using an antibody specific to the glycine-extended (nonamidated) form of CgA (CgA-Gly), we also observed an accumulation of CgA-Gly in EndoC-β H1 cells treated with PAM siRNA by western blot analysis (Fig. 7d,e and Supplementary Fig. 8 for full blots). Treatment of cells with 4-phenyl-3-butenoic acid (4P3BA), an irreversible inhibitor of PAM catalytic activity, produced similar results, showing that this effect is not due to off-target effects. In both cases, the ratio of non-amidated CgA to total CgA was significantly increased following perturbation of PAM (+ 226%, P = 0.016 for PAM knockdown; + 282%, P = 0.043 for PAM inhibition) (Fig. 7d ) 44, 45 . Thus, CgA is a plausible PAM substrate in β -cells and a strong candidate for mediating the effects of PAM on β -cell function. In contrast, silencing of IAPP in EndoC-β H1 cells had no effect on insulin content or secretion ( Supplementary Fig. 4c-f) .
Finally, we attempted to detect patterns of CgA amidation in primary human islets by immunostaining pancreatic sections from a subset of six risk allele carriers and six matched controls (a subset of the donors analyzed by electrophysiology). By co-staining for insulin and either CgA-Gly or total CgA, we successfully identified CgA in the endocrine component of the pancreas (Supplementary Fig. 9a ). Using a mask to focus exclusively on insulin-positive β -cells, we then quantified average intensities and derived a ratio of nonamidated to total CgA. The results were highly variable, with more than a 15-fold discrepancy between the lowest (6.89%) and highest (109%) ratios. Thus, no overall difference was detected between carriers and controls (P = 0.90) ( Supplementary Fig. 9b) ; larger studies may be required to detect any amidation defects in risk carriers. , then analyzed by western blot using antibodies specific for non-amidated CgA (CgA-Gly) and total CgA. Control levels are indicated in d by the dashed grey line. Results in e are representative of n = 5 independent experiments for PAM silencing, and n = 3 independent experiments for PAM inhibition. Corresponding unedited blots are provided in Supplementary Fig. 8 . b,c, P values * < 0.05, ** < 0.01, *** < 0.001 for paired, two-tailed Student's t-tests where a single independent variable was being tested. a,d, Two-way analysis of covariance (ANCOVA) followed by Tukey's HSD post-hoc test where two experimental variables were being tested. All box plots display the interquartile range (IQR) with medians, whiskers indicating 1.5 × the IQR and individual data points. WCE, whole-cell extract.
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Discussion
Recent efforts to catalog coding variants associated with T2D risk have identified two independent association signals in the PAM gene 3, 6, 8 . The coding risk alleles are associated with a decreased insulinogenic index, a physiological measure of insulin secretion in response to a glucose challenge, indicating a likely endogenous role for PAM in β -cell function. Here, we provide evidence that both T2D risk alleles reduce overall PAM activity. While the risk allele at rs78408340 causes defective PAM expression, our results demonstrate that the risk allele at rs35658696 acts through a dual mechanism of reduced catalytic function and, albeit to a lesser extent, decreased expression.
We have further shown that reduced PAM activity causes β -cell dysfunction through multiple effects on insulin availability and the dynamics of granule exocytosis. Importantly, these defects preferentially affect insulin secretion under stimulated conditions, leading to a blunted glucose response. Taken together, our findings support a molecular mechanism whereby T2D risk alleles in PAM decrease PAM function, directly impacting on the ability of pancreatic β -cells to mobilize insulin in response to glucose.
This novel mechanism provides an explanation for the relatively larger effect size of rs78408340 (p.Ser539Trp) compared with rs35658696 (p.Asp563Gly), as reported in two independent GWAS for T2D risk and insulinogenic index 6, 8 . Mislocalization or misexpression of p.Ser539Trp PAM would presumably compromise function more severely than the combined reduction in amidation activity and expression observed for p.Asp563Gly PAM. This is particularly true for cell types in which the luminal form predominates over the integral form of PAM, since misexpressed p.Ser539Trp PAM may retain some residual function. The precise cellular dynamics that yield luminal PAM in β -cells have not been elucidated; however, it appears generally to be more predominant in neuroendocrine cell types 17 . This raises the intriguing possibility of tissue-specific differences in PAM activity for rs78408340 risk allele carriers.
To explore the molecular mechanism underlying β -cell dysfunction in PAM risk allele carriers, we performed detailed characterizations in primary islets and the human β -cell line EndoC-β H1. The observed defects were broadly similar, with significant reductions in insulin secretion driven by decreased insulin content. Further, the size of the RRP was diminished in both primary β and EndoC-β H1 cells. However, total exocytosis remained unaffected, which is consistent with the lack of effect on content-normalized insulin secretion. Taken together, these results highlight a defect in insulin mobilization mediated through granule biogenesis and trafficking.
Interestingly, the phenotype caused by reduced PAM activity was consistently more pronounced under stimulated conditions. In EndoC-β H1 cells, insulin secretion was not affected in low glucose and the stimulation index (ratio of high to basal secretion) was significantly reduced. In primary β -cells, defects in exocytosis were apparent only in 10 mM glucose, with normal levels in basal glucose. Moreover, insulin secretion from intact islets was significantly reduced under stimulated conditions only and with a significant interaction between genotype status and glucose levels. PAM lossof-function in β -cells thus manifests preferentially under conditions resembling the fed state in vivo, in line with the association of the T2D risk alleles with a reduced insulinogenic index.
Our molecular studies in EndoC-β H1 cells also confirmed that CgA is a substrate for PAM amidation in β -cells 45 . CgA is a granular packaging protein known to influence vesicle composition in other neuroendocrine cell types by facilitating the condensation of secreted proteins within nascent secretory vesicles [39] [40] [41] [46] [47] [48] . Previous studies using global Chga knockout mouse models have attempted to investigate a role for CgA in pancreatic islets. However, they have been confounded by compensatory increases in other granin proteins, including chromogranin B 49, 50 . In mice, knockdown of chromogranin B leads to strong inhibition of insulin secretion by mechanisms that have not been resolved 51 . Our results suggest a model whereby amidation of CgA by PAM enhances its ability to aggregate and package insulin efficiently in granules. In support of this hypothesis, amidation of numerous biological peptides has been shown to promote protein structure and self-aggregation due to improved electrostatic interactions [52] [53] [54] . C-terminal cleavage of CgA also increases protein stability in pituitary cells 55, 56 . More detailed studies in primary islets is required to confirm any defective amidation of CgA in risk allele carriers.
Although our tissue expression analyses showed that PAM is highly expressed in pancreatic islets, the results also revealed PAM to be widely expressed across a range of other cell types. It is therefore possible that PAM could indirectly modulate β -cell function via amidated signals released from other tissues 23, 57 . Glucagon-like peptide 1 (GLP-1) is an amidated peptide released from intestinal L cells that amplifies insulin secretion in response to a meal 58 . Moreover, GLP-1 (7-36) amide has an increased half-life compared to GLP-1 (7-37) in vitro, suggesting that amidation could lead to elevated GLP-1 levels in the circulation 59 . Therefore, PAM may have endocrine effects on β -cell function via decreased GLP-1 amidation and/or secretion, with possible implications for genotype-specific responses to incretin-based therapies.
Within the β -cell, it remains likely that additional PAM substrates may exist, some of which could further modulate insulin mobilization. We also cannot exclude the possibility of pleiotropic effects at the level of the T2D risk alleles; nevertheless, the presence of two independent coding variants in PAM strongly favor a primary causal mechanism mediated through PAM. This is further supported by our experimental findings, which establish direct impacts on PAM function and expression.
In conclusion, we have shown that the amidating enzyme PAM is a critical component of the regulated secretory pathway in β -cells, consistent with the observed effects of PAM missense variants on T2D risk and the insulinogenic index. Our results establish molecular mechanisms for T2D-associated PAM risk alleles and show multiple effects of reduced PAM function on insulin granule packaging and release. Our study illustrates the importance of coding variants implicated in disease risk for the identification of candidate causal genes. Further work is required to explore the possible contribution of other tissues to the effect of PAM risk alleles, particularly those that have implications for incretin-based therapies.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0173-1. Cloning of PAM expression plasmids. We purchased a pCMV6 expression vector encoding integral membrane Homo sapiens PAM (NM_138821.2) with an in-frame C-terminal Myc-Flag tag (PAM-Myc-Flag) from Origene. Luminal functional PAM-Myc-Flag encompassing the first 710 amino acids was generated via PCR using the primers luminal (F) and luminal (R) (Supplementary Table 2 ). Puromycin-resistant PAM-Myc-Flag expression vectors were generated via BglII/ XmaI digestion, blunt ending with T4 DNA polymerase and subcloning into HpaIdigested pIRES puro 2 (Takara Bio USA). Protein alterations were introduced via site-directed mutagenesis using the Stratagene QuikChange II kit (Agilent Biotechnologies), according to manufacturer's instructions, with the following primers: SDM_S539W_F and SDM_S539W_R for generating p.Ser539Trp PAM; SDM_D563G_F and SDM_D563G_R for generating p.Asp563Gly PAM; and SDM_Y651F_F and SDM_Y651F_R for generating p.Tyr651Phe PAM (Supplementary Table 2 ). All plasmids were verified by sequencing.
Cell culture and transfection. Primary human islets were freshly isolated from deceased donors at the Oxford Centre for Islet Transplantation in Oxford, UK or at the Alberta Diabetes Institute IsletCore as previously described 60, 61 . Islets were then cultured in CMRL medium (Thermo Fisher Scientific) at 37 °C or kept in UW cold storage solution (Viaspan) at 4 °C for short-term storage before being processed. HEK293 cells were routinely passaged in DMEM 6429 (Sigma-Aldrich) supplemented with 10% fetal calf serum, 50 international units ml −1 penicillin and 50 µ g ml −1 streptomycin. EndoC-β H1 cells were routinely passaged in growth medium supplemented with 5.5 mM glucose 24 . All cells were maintained at 37 °C and 5% CO 2 .
To generate PAM stable cell lines, HEK293 cells were transfected using FuGENE 6 (Promega Corporation), according to the manufacturer's instructions. Cells were routinely passaged and maintained them in 1 µ g ml −1 puromycin. For fluorescence microscopy, EndoC-β H1 cells were transfected in chamber slides (BD Biosciences) using FuGENE 6. For siRNA experiments, EndoC-β H1 cells were seeded in Opti-MEM reduced serum-free medium (Thermo Fisher Scientific) containing 25 nM ON-TARGET plus SMARTpool siRNA complexes (Dharmacon) preformed with Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific), according to the manufacturer's instructions. Growth medium was replaced 24 h later and cells were incubated for a further 48 h. For PAM inhibitor experiments, seeded cells were treated with 500 µ M 4P3BA or dimethylsulfoxide vehicle (Sigma-Aldrich) for 72 h.
Recombinant PAM protein production. HEK293 stable cell lines were seeded into Nunc TripleFlasks (Thermo Fisher Scientific). The medium was replaced with DMEM 1145, supplemented with 1 mM sodium pyruvate and incubated for 3-5 days. Supernatant containing luminal recombinant PAM protein was harvested directly from the flasks, filtered into a sterile storage bottle (Corning GmbH) and pH corrected to 5.5 with HCl. The filtered supernatant was concentrated using a Centricon Plus-70 Centrifugal Filter Device (Millipore Limited) with a 30 kDa molecular weight cutoff, according to the manufacturer's instructions.
Quantitation of recombinant PAM.
For the relative quantitation of recombinant PAM proteins, 3 × 1 µ l aliquots of concentrated supernatant were separated on a 4-20% Criterion TGX Stain-Free Precast Gel (Bio-Rad Laboratories, Inc) and transferred to polyvinylidene difluoride using a Trans-blot Turbo Transfer Pack (Bio-Rad Laboratories), according to the manufacturer's instructions. Membranes were incubated overnight in 4A6 anti-Myc tag antibody (Millipore Limited) at 4 °C and developed using the Clarity Western ECL Blotting Substrate (Bio-Rad Laboratories), according to manufacturer's instructions. Proteins were visualized on a ChemiDoc MP (Bio-Rad Laboratories). Lanes and bands were drawn in the Image Lab version 5.0 for Windows software; the average band volume (intensity) was quantified for each triplicate of samples. The amount of recombinant variant PAM protein per µ l was then calculated relative to wild-type PAM.
Kinetic analysis of PAM amidating activity. We used the spectrophotometric detection of chemically converted glyoxylate to measure the amidating activity of PAM 20 . An assay mix of 100 mM MES pH 5.5, 2 µ M copper sulfate, 10 mM L-ascorbic acid, 0.1 mg ml −1 bovine liver catalase and 20 mM hippuric acid (Sigma-Aldrich) was split into glass vials. Equimolar amounts of recombinant PAM were added to each vial and incubated in a 37 °C water bath. Every 30 min, samples were removed to a conical 96-well plate (4titude Limited) containing 40 mM EDTA pH 8.0. The glyoxylate produced was converted to glyoxylate phenylhydrazone by adding 0.1% phenylhydrazine-HCl (Sigma-Aldrich) to the plate, incubating it at room temperature for 15 min and saturating it with concentrated (37%) HCl. The contents of the entire plate were then aspirated and dispensed into a flat-bottomed 96-well plate (Corning GmbH) containing 0.2% potassium ferricyanide using an i-Pipette Automated Pipettor (Apricot Designs). We measured the absorbance of 1,5-diphenylformazan at 515 nm using a VersaMax Microplate Reader (Molecular Devices, LLC).
Kinetic analysis of variant PAM substrate affinity. For the K m calculations, a 12-point, twofold serial dilution of hippuric acid in which the maximum concentration was 20 mM was prepared in the assay mix (100 mM MES pH 5.5, 2 µ M CuSO 4 , 10 mM L-ascorbic acid, 0.1 mg ml −1 bovine liver catalase). Recombinant PAM or empty vector control supernatant was then added. The amount of p.Asp563Gly PAM added to the assay was increased so that it displayed an equal V max to wild-type PAM. The volume of empty vector supernatant matched the volume of wild-type PAM used in that experiment. Vials were incubated in a 37 °C water bath for 1 h. Samples were then removed into a conical 96-well plate containing 40 mM EDTA pH 8.0. TaqMan . Pooled mouse islet RNA was sourced from four 12-28-week-old Naval Medical Research Institute mice. Hypothalamic and pituitary RNA were commercially sourced from AMS Biotechnology Ltd. Complementary DNA was generated using the GoScript Reverse Transcription System (Promega Corporation), according to the manufacturer's instructions, and analyzed with the 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific). C t values were normalized to the combined average of the housekeeping genes peptidylprolyl isomerase A (PPIA) and TATA-box binding protein (TBP). PAM expression in sorted β -cells and non-β -cells was analyzed based on previously published RNA sequencing data 22 . Allele-specific expression was performed using publicly available RNA sequencing data from the previously described islets of 118 individuals 34 . In brief, 40 samples were freshly isolated at the Oxford Centre for Islet Transplantation as described 60 . The other samples, from Edmonton, Canada, were either extracted from the long-term cryopreserved biobank and thawed as described 62 (n = 65) or freshly isolated from donor pancreas (n = 13). Poly-A selected libraries were prepared from total RNA at the Oxford Genomics Centre, multiplexed (3 samples per lane) and clustered; 100 nucleotide paired-end reads were sequenced using Illumina TruSeq v3 chemistry on the Illumina HiSeq 2000 Sequencing System (Illumina, Inc). DNA was extracted from the spleen or the exocrine fraction of the islet for most donors, or from the islets when no other tissue was available. All samples were genotyped on the Illumina Omni2.5 Exome-8 version 1.3 BeadChip array.
Gene expression analyses. Gene expression was measured with
In total, 11 out of 118 individuals were heterozygous at rs35658696 and were thus used for allele-specific expression analysis. Reads were mapped with the WASP pipeline 35 combined with the Spliced Transcripts Alignment to a Reference (STAR) aligner 63 and based on human genome assembly GRCh37.75 64 . The WASP pipeline removes reads with evidence of mapping bias. Final allele counts were then calculated with an allele counter 65 and a binomial test for allelic imbalance was performed in R against a null allelic proportion of 0.5.
Associations for rs35658696 (p.Asp563Gly) and rs78408340 (p.Ser539Trp) with PAM protein plasma levels in humans were looked up in the supplementary material to the article by Sun et al. 33 . Association analyses in their study had been performed within a linear regression framework under an additive model, adjusting for age, sex, time between sampling and processing, and three principal components. Effect directions were then aligned to correspond to the T2D risk alleles.
Immunofluorescent labeling and microscopy. Human pancreatic specimens fixed in 10% formalin and embedded in wax were used to localize PAM in islets. Sections of 4 μ m were de-waxed, rehydrated and heated to 95 °C in 10 mmol l −1
Tris + 1 mmol l −1 EDTA pH 6.0 for 10 min for antigen retrieval. Tissue sections were incubated overnight in anti-PAM antibody (ab109175; Abcam), guinea pig anti-insulin antibody (in-house antibody) and mouse anti-glucagon antibody (G2654; Sigma-Aldrich). PAM immunoreactivity was enhanced using a tyramide signal amplification step (Thermo Fisher Scientific) and visualized with Alexa Fluor 488 (Thermo Fisher Scientific). Insulin and glucagon were visualized with Alexa Fluor 633 (Thermo Fisher Scientific) and anti-mouse tetramethylrhodamine (Sigma-Aldrich), respectively.
EndoC-β H1 cells transfected with PAM expression vectors were fixed in 4% paraformaldehyde, permeabilized in 0.1% (v/v) Triton X-100 and blocked in 10% (w/v) bovine serum albumin. Primary antibodies (4A6 anti-Myc, Belfast antiinsulin, TGN46 anti-trans Golgi (Sigma-Aldrich) and H-70 anti-calnexin (sc-11397; Santa Cruz Biotechnology, Inc)) were incubated overnight at 4 °C.
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Slides were then incubated in Alexa Fluor-conjugated secondary antibodies (Thermo Fisher Scientific) and mounted in VECTASHIELD Mounting Medium with DAPI (Vector Laboratories Ltd). Cells were visualized with a Zeiss LSM 510 META confocal laser scanning module arranged on an Axiovert 200 microscope and a Plan-Apochromat 63× /1.4 oil immersion objective (Carl Zeiss). An argon laser was used to excite Alexa Fluor 488 at λ = 488 nm; helium-neon lasers 543 and 633 were used to excite Alexa Fluor 543 at λ = 543 nm and Alexa Fluor 633 at λ = 633nm, respectively. The signals were collected between 640 and 694 nm for Alexa Fluor 633, between 512 and 533 nm for Alexa Fluor 488, and between 587 and 619 nm for Alexa Fluor 543. The main dichroic beam splitter (HFT 488/543/633) was combined with a secondary one, either the NFT490 or NFT545 or NFT635vis. DAPI was excited in two-photon mode using the 740-nm line of an infrared light Chameleon laser combined with an HFT KP 650 filter (Carl Zeiss).
Gene silencing in EndoC-βH1. To perform gene silencing by RNA interference, a master mix of Opti-MEM reduced serum-free medium (Thermo Fisher Scientific) was pre-mixed with 0.4% RNAiMAX transfection reagent (Thermo Fisher Scientific) and 50 nM siRNA (commercially available SMARTpools from Dharmacon against PAM, CHGA or IAPP as indicated). The solution was then incubated at room temperature for 15 min to form siRNA-lipid complexes before 50 μ l of the master mix was added to each well on a 96-well black OPTI-plate (Corning GmbH). Cells resuspended in standard culturing media were added in a 1:1 volume until a final density of 75,000 cells cm −2 and siRNA concentrations of 25 nM were reached. After 24 h, the transfection media were replaced with complete culturing media. After a further 2 days, cells were taken forward for functional assays or gene expression analyses as required.
Insulin secretion assays in EndoC-βH1. Seventy-two hours after gene silencing, cells prepared as described earlier were starved overnight in standard cell culture medium supplemented with glucose to a final concentration of 2.8 mM. Following overnight incubation, cells were further incubated for 1 h in culture medium with 0 mM glucose. The medium was then replaced with the appropriate conditions to initiate secretion in static incubation. After 1 h, supernatants were harvested in a staggered fashion, leaving a residual volume of supernatant (~30 μ l in 96-well format) to minimize disturbances of the adherent cells. Supernatant samples were then centrifuged at 300 g in a pre-chilled centrifuge for 5 min and a small volume of the supernatant was transferred to a new plate.
Meanwhile, adherent cells were processed for cell counting based on the CyQUANT Direct Cell Proliferation Kit (Thermo Fisher Scientific), according to the manufacturer's recommendations. Briefly, residual medium was replaced with medium supplemented with 0.2% direct nucleic acid dye and 1% background suppressor dye. Cells were then incubated for 1 h at 37 °C in the dark and fluorescence was measured on the EnSpire Multimode Plate Reader (PerkinElmer) using fluorescein isothiocyanate filter settings (ex480/em535 nm). Cell counts were expressed as relative fluorescence units (RFU) normalized to the earliest time point. Following the CyQUANT assays, cells were washed once in standard media, before adding ice-cold acid-ethanol buffer (1.5% concentrated HCl, 75% ethanol and 23.5% deionized water) to extract the intracellular insulin content. Plates were then covered with parafilm to prevent evaporation and stored at − 20 °C for shortterm storage or − 80 °C for long-term storage.
To analyze the insulin samples, the Insulin (human) AlphaLISA Detection Kit (PerkinElmer) was used to measure the concentrations of both supernatants and cellular contents. Samples were diluted in 1 × AlphaLISA immunoassay buffer (1:10 for supernatants and 1:200 for contents) and then analyzed in white 1/2 AreaPlate-96 (PerkinElmer) on the EnSpire using the AlphaScreen protocol (PerkinElmer), according to the manufacturer's recommendations. Normalized secretion values were calculated on a per-well basis as the ratio of total secreted insulin to total intracellular insulin content (%), or as the ratio of total secreted insulin to cell counts (pg/RFU), which were averaged across replicates. Corrected values were then normalized to basal insulin secretion rates for negative control on a per-experiment basis to eliminate variability in baseline secretion rates across independent experiments.
Insulin secretion assays in primary human islets. Insulin secretion assays were performed on intact human islets isolated from 16 risk allele carriers and 16 controls, matched for age (P = 0.88), sex, BMI (P = 0.88) and time of isolation. The experiments were performed at 37 °C in Krebs-Ringer buffer (KRB) (NaCl 115 mM; KCl 5 mM; NaHCO 3 24 mM; CaCl 2 2.5 mM; MgCl 2 1 mM; HEPES 10 mM; 0.1% bovine serum albumin, pH 7.4) with glucose concentrations as indicated. For each donor, triplicate groups of 15 handpicked human islets were pre-incubated for 2 h with 1 mM glucose KRB. Islets were subsequently incubated for 1 h in 1 mM glucose KRB, after which supernatants were collected and replaced with 10 mM or 16.7 mM glucose KRB. After another hour, supernatants were again collected, and total insulin content extracted from the islet pellet using acid-ethanol. Samples were stored at − 20 °C and assayed for insulin via electrochemiluminescence (Meso Scale Discovery, Rockville, MD, USA or ALPCO, Salem, NH, USA). Insulin secretion measurements at 1 mM and 16.7 mM glucose were performed for all individuals (n = 16 per group); measurements at 10 mM glucose were performed for a subset hereof (n = 9 per group). Averages were calculated after excluding any outliers using Grubb's test, and either displayed as raw values or normalized to insulin content on a per-individual basis.
Membrane capacitance assays in EndoC-βH1. Electrophysiological measurements were performed using an HEKA EPC10 Patch Clamp Amplifier (HEKA Elektronik Dr. Schulze GmbH) at 32 °C using the standard whole-cell configuration as previously described 66 . The pipette solution (intracellular medium) contained 125 mM Cs-glutamate, 20 mM CsCl, 15 mM NaCl, 1 mM MgCl 2 , 5 mM HEPES, 0.05 mM EGTA, 0.1 mM cAMP and 3 mM Mg adenosine triphosphate (pH 7.15 with CsOH). The extracellular solution contained 1 mM glucose, 118 mM NaCl, 5.6 mM KCl, 1.2 mM MgCl 2 , 5 mM HEPES and 2.6 mM CaCl 2 (pH 7.4 with NaOH). Tetraethylammonium chloride (20 mM) was added to block residual potassium currents. Calcium sensitivity of the vesicles was inferred from the relationship between calcium current density and exocytosis. The calcium current was measured at the first pulse, after inactivation of the sodium current (5 ms).
Analysis of exocytosis in primary human β-cells. Human pancreatic islets were isolated and prepared at the Alberta Diabetes Institute IsletCore as previously described; these had already been genotyped 34, 61 . Single-cell capacitance responses were monitored as described earlier for EndoC-β H1 cells (including 0.1 mM cAMP), with an additional pre-incubation period of 1 h at 1 mM glucose. Following recordings, cells were positively identified by insulin immunostaining. The kinetics of exocytosis were examined at 1 and 10 mM glucose for seven risk allele carriers and seven controls, matched as groups for age (P = 0.52), sex and BMI (P = 0.68). The total number of cells per individual were [3; 5; 6; 6; 7; 8; 10] (low glucose, controls), [2; 3; 6; 7; 7; 7; 9] (high glucose, controls), [3; 4; 4; 5; 6; 8; 12] (low glucose, carriers), and [4; 4; 4; 6; 6; 8; 8] (high glucose, carriers). Mean capacitance was calculated per condition for each depolarization step.
Electron microscopy. Primary islets or EndoC-β H1 cells were fixed in 2.5% glutaraldehyde, post-fixed in 2% uranyl acetate, dehydrated in graded methanol and embedded in London Resin Gold (Agar Scientific Ltd). Ultrathin sections cut onto nickel grids were immunolabeled for PAM (ab109175; Abcam) followed by anti-rabbit biotin (Vector Laboratories Ltd) and streptavidin gold 15 nm (British Biocell International). For EndoC-β H1 cells, insulin was immunolabeled with an in-house antibody followed by anti-guinea pig gold 10 nm (British Biocell International). Sections were viewed on a JEOL JEM-1010 microscope (accelerating voltage 80 kV) with a digital camera (Gatan, Inc.). To estimate PAM concentration in secretory vesicles, quantification of immunogold labeling was performed by a blinded observer using the ImageJ software. The following parameters were determined: cross-sectional vesicle area; vesicle density (number of vesicles per cytoplasmic area); and insulin or PAM labeling per vesicle (number of immunogold particles per vesicle).
Western blot analysis of CgA amidation. To mimic the effect of gene silencing, cells were cultured for 24 h with the irreversible PAM inhibitor 4P3BA (Sigma-Aldrich) at a concentration of 500 μ M
45
. Whole-cell extracts from siRNA or inhibitortreated EndoC-β H1 cells were prepared as previously described 67 . Supernatant was harvested directly from cells and filtered with a 0.22-μ m filter. Protein yields were determined with the Bio-Rad Protein Assay (Bio-Rad Laboratories), according to the manufacturer's instructions. For western blotting, 10 μ g whole-cell extract and 0.5% total supernatant volume were analyzed with denaturing SDS-PAGE. Antibodies specific for CgA-Gly (ab52983; Abcam) 45 and total CgA (ab15160; Abcam) were used to calculate the ratio of amidated to non-amidated CgA using the Image Lab, version 5.0 for Windows (Bio-Rad Laboratories).
Immunohistochemistry of human pancreatic sections. Paraffin-embedded human pancreas biopsy sections were rehydrated, and citrate buffer antigen retrieval was performed. Consecutive 5-µ m sections were stained for either total CgA (ab15160, 1:100; Abcam) or CgA-Gly (ab52983, 1:100; Abcam), plus insulin (1:500; Dako Canada) at 4 °C overnight. Species-specific secondary antibodies were Alexa Fluor 488 or 594 conjugates (Thermo Fisher Scientific) diluted 1:400 in 2% goat serum. Slides were cover-slipped with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific). Images were acquired with an Olympus VS120 slide scanner (Olympus Canada Inc., Richmond Hill, Ontario, Canada), utilizing excitation filter wavelengths of 432 nm for DAPI, 515 nm for AlexaFluor 488 and 595 nm for AlexaFluor 594. Images were analyzed with the Olympus VS120-S6 analysis software (Olympus Corporation, Shinjuku, Tokyo, Japan. Olympus VS120-S6-ASW 2.9 [Build 13741] for Windows). and the ratio of mean total CgA and CgA-Gly signal intensity of paired insulin-positive regions was calculated.
Statistics. All statistical analyses were performed in R version 3.3.1 for Windows, except electron microscopy data and electrophysiological measurements in EndoC-β H1 cells, which were analyzed with the OriginPro software, version 8.5.1 for Windows (OriginLab Corporation). For kinetic data, rates were found to be dependent on substrate concentration; exponential models were fitted. Enzyme kinetics, electron microscopy, electrophysiological and cellular assay data were analyzed with two-tailed Student's t-tests where a single independent variable was being tested, and with two-way analysis of covariance (ANCOVA) followed by Functional and transcriptomic data from primary islets were analyzed based on the maximum number of risk allele carriers available in the combined collection of islets from study centers in Oxford, UK, and Edmonton, Canada. For cellular data, effect sizes could not be estimated prospectively (precluding power analysis), and standard scientific conventions were followed for these studies. Specifically, for insulin secretion and exocytosis experiments, three independent passages of cells were analyzed in biologically independent replicates. In each case, cells were only taken forward for detailed phenotyping if a satisfactory glucose responsiveness (fold induction > 1.5) could be ascertained. For the quantitative electron microscopy, a total of ten cells were counted per treatment. Tissue expression panels were analyzed in single replicates of pooled tissues (full information available from commercial suppliers, as stated in the methods). In the case of determining CgA amidation status, additional replicates were requested at the revision stage; the estimated effect size derived from the first set of experiments was used to inform the level of replication required in the follow-up analysis.
Data exclusions
Describe any data exclusions. To remove significant outliers among technical replicates for primary islet data, Grubbs outlier test was systematically applied on a per-individual basis.
Replication
Describe whether the experimental findings were reliably reproduced.
For the human islet data, replication could not be attempted due to the difficulties in obtaining primary islets from cadaveric donors and the low frequency of the T2D risk alleles in PAM. Several aspects of the cellular data, including insulin secretion defects, have been replicated by parallel studies in the lab, and on-going work has successfully replicated the effects of the PAM variants in kinetic assays. Electron microscopy was independently quantified by two blinded observers, identifying the same overall trends. Western blotting following PAM knockdown or inhibition was successfully reproduced in at least three different passages of the cell line, in experiments performed by two independent researchers.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
PAM variant carriers were matched for age, gender, and BMI to available controls in the same cohort of primary human islets (n = 187). For cellular phenotyping, samples were randomly positioned on microplates to minimize any possibly systematic bias from technical artefacts.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The post-hoc matching of islet samples was performed based on the three listed covariates and sample genotype, with the researcher being blinded to experimental data. All subjective quantifications of cellular data, including the scoring of electron micrographs, were performed by blinded observers.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Data were analysed using:
• Olympus VS120-S6 analysis software, • OriginPro V8.5.1 • ImageJ 1.52b
• Image Lab 5.0 • R version 3.3.1 using the following standard packages: drc, ggplot2, mass, pwr, scales, stats.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All unique materials used are available from the authors upon request or from standard commercial sources (as indicated in relevant sections of the online methods), except the cell line, EndoC-βH1, which is available from UnivercellBiosolutions (formerly EndoCells), subject to an MTA.
